Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
80 hedge funds and large institutions have $266M invested in Bellicum Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 7 closing their positions.
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
21% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 24
14% more funds holding
Funds holding: 70 → 80 (+10)
5% less call options, than puts
Call options by funds: $622K | Put options by funds: $656K
28% less capital invested
Capital invested by funds: $370M → $266M (-$103M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$4.44M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$3.84M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.64M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$2.08M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.34M |
| 2 |
JP Morgan Chase
New York
|
-$1.94M |
| 3 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$1.55M |
| 4 |
First Eagle Investment Management
New York
|
-$1.4M |
| 5 |
QF
QVT Financial
New York
|
-$904K |
BLCM Hedge Fund Activity: Q4 2016 in Review
80 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2016, worth a combined $266M — down 28% from $370M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new BLCM positions and 7 closed out — a net gain of 10 holders — while 29 added to existing stakes and 24 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $4.44M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.34M.
- 80 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2016, up from 70 in Q3 2016.
- Funds reported $266M of Bellicum Pharmaceuticals, Inc. stock for Q4 2016, down 28% quarter-over-quarter.
- 17 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2016 and 7 closed out, a net change of +10 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2016 was Eventide Asset Management, an estimated $4.44M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q4 2016 was T. Rowe Price Associates, an estimated $3.34M sold.
Based on aggregated 13F filings for Q4 2016.